<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679455</url>
  </required_header>
  <id_info>
    <org_study_id>ML39235</org_study_id>
    <nct_id>NCT03679455</nct_id>
  </id_info>
  <brief_title>A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1</brief_title>
  <acronym>OBI-1</acronym>
  <official_title>A Multicenter, Single-arm, Phase II Study to Evaluate a Safety and Efficacy of Obinutuzumab Induction Followed by 2 Years of Maintenance in Patients With Relapsed/Refractory Waldenström Macroglobulinemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Myeloma Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioscience, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Myeloma Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, single-arm, open label, non-randomized, phase II study designed to
      investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in
      patients with relapsed/refractory Waldenström Macroglobulinemia (R/R MW).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to investigate the efficacy, safety and tolerability of obinutuzumab administered as
      monotherapy in patients with relapsed/refractory Waldenström Macroglobulinemia (R/R WM)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multi-center, single-arm, open label, non-randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to 3,5 years</time_frame>
    <description>BOR is the best response recorded from the start of the treatment until disease progression: response assessments recorded as CR, VGPR, PR, MR, SD, PD. As a responder is considered patient with at least MR (CR, VGPR, PR, MR). BOR will be presented as rates with corresponding exact 95% CI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 3,5 years</time_frame>
    <description>PFS will be calculated as time from fist treatment dose until progression or death of any cause. The PFS will be defined as well-documented and verifiable data. The Kaplan-Meier curve will be provided. The median time to PFS along with associated 95% confidence interval will be provided as well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from first study treatment dose till 1 year after the treatment period</time_frame>
    <description>OS is defined as time from first study treatment dose to death due to any cause. Survival distributions will be estimated using the Kaplan-Meier method. Each subject will be followed for 1 year after the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>after 6 Cycles of obinutuzumab treatment (after induction phase); each cycle is 21 days in Induction Phase;</time_frame>
    <description>ORR as a secondary endpoint will be assessed after completion of induction phase and after maintenance phase. Responders include subjects with at least MR (CR, VGPR, PR, MR). Non-responders include subjects with Stable Disease (SD) and Progressive Disease (PD). Subjects with unknown or missing responses will be considered as non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>after all 12 Cycles of treatment in Maintenance Phase (at first visit in follow-up phase FU2M) or after the last dose, if not after 12 Cycles of obinutuzumab (each cycle is 8 weeks in Maintenance Phase;</time_frame>
    <description>ORR as a secondary endpoint will be assessed after completion of induction phase and after maintenance phase. Responders include subjects with at least MR (CR, VGPR, PR, MR). Non-responders include subjects with Stable Disease (SD) and Progressive Disease (PD). Subjects with unknown or missing responses will be considered as non-responders.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab 25 MG/ML</intervention_name>
    <description>Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Gazyvaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to beginning study-related procedures.

          2. Male and female subjects aged ≥ 18 years.

          3. Able to comply with the study protocol, in the investigator's judgment.

          4. Confirmed clinicopathological diagnosis of WM with detectable CD20 positive of the
             tumor cells

          5. Measurable disease defined as serum monoclonal IgM &gt;0.5 g/dL

          6. Active disease and indication for treatment based on the Seventh IWWM recommendations
             (Dimopoulos et al., 2014) defined by presence of at least any one of the following
             conditions:

               -  Recurrent fever, night sweats, weight loss, fatigue

               -  Hyperviscosity

               -  Lymphadenopathy which is either symptomatic or bulky (≥5 cm in maximum diameter)

               -  Symptomatic hepatomegaly and/or splenomegaly

               -  Symptomatic organomegaly and/or organ or tissue infiltration

               -  Peripheral neuropathy due to WM

               -  Symptomatic cryoglobulinemia

               -  Cold agglutinin anemia

               -  Immune hemolytic anemia and/or thrombocytopenia

               -  Nephropathy related to WM

               -  Amyloidosis related to WM

               -  Hemoglobin ≤10 g/dL

               -  Platelet count &lt;100 × 109/L

          7. Subjects must have received prior therapies for their WM and have relapsed or
             refractory WM requiring therapy. Any number of prior therapies is acceptable. Relapsed
             WM: defined as a subject who has received at least one prior WM therapy and previously
             achieved a complete or partial remission/response lasting at least 6 months Refractory
             WM: is defined as progression on treatment; disease progression &lt; 6 months of the last
             anti-WM therapy

          8. Subjects must have adequate organ and marrow function as defined below:

               -  Absolute neutrophil count ≥ 1.5 x 109/l (unless decreased due to WM involvement
                  of the bone marrow)

               -  Platelets ≥ 75 x 109/l (unless decreased due to WM involvement of the bone
                  marrow)

               -  Hemoglobin ≥ 9 g/dL

               -  Total bilirubin ≤ 1.5 x ULN or &lt; 2 x ULN if attributable to hepatic infiltration
                  by neoplastic disease

               -  AST and ALT &lt; 2.5 x ULN

               -  Calculated creatinine clearance by Cockcroft-Gault formula &gt;40 mL/min

               -  INR ≤ 1.5

          9. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

         10. Fertile men or women of childbearing potential, unless ≥ 2 years after the onset of
             menopause (for women), must be willing to use a highly effective contraceptive method
             (Pearl Index &lt; 1) such as oral contraceptives, intrauterine device, sexual abstinence
             or barrier method of contraception in conjunction with spermicidal jelly, during study
             treatment and for 18 months after end of obinutuzumab treatment.

        Exclusion Criteria:

          1. Lactating women, women with a positive pregnancy test at Visit 1 or women (of
             childbearing potential) as well as men with partners of childbearing potential, who
             are not willing to use adequate contraception from study start through 18 months after
             end of obinutuzumab treatment.

          2. Known involvement of the central nervous system by WM.

          3. Vaccination with a live vaccine a minimum of 28 days prior to study enrolment
             (vaccination day considered as Day 0).

          4. History of stroke or intracranial hemorrhage within 12 months prior to study
             enrollment.

          5. Currently active, clinically significant cardiovascular disease.

          6. Any active systemic infection. Caution should be exercised when considering the use of
             obinutuzumab in patients with a history of recurring or chronic infections.

          7. Positive for hepatitis C antibody at screening.

          8. Positive test result for chronic hepatitis B virus (HBV) infection (defined as a
             positive HBsAg serology). Patients with occult or prior HBV infection (defined as
             negative hepatitis B surface antigen [HBsAg] and positive total hepatitis B core
             antibody [HBcAb]) may be included if HBV DNA is undetectable, provided that they are
             willing to undergo monthly DNA testing during treatment and follow-up until 12 months
             after the last dose of obinutuzumab.

          9. Known HIV infection at screening.

         10. Any serious illness, medical condition, organ system dysfunction or abnormality in
             clinical laboratory test that, in the investigator's opinion, could compromise the
             subject's safety or put the study outcomes at undue risk.

         11. Concurrent use of other anti-cancer agents or treatments.

         12. Prior use of any investigational monoclonal antibody therapy within 6 months of study
             start.

         13. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy,
             known hypersensitivity to any of the study drugs or sensitivity to murine products.

         14. Treatment with any known non-marketed drug substance or experimental therapy within 5
             terminal half-lives or 4 Weeks prior to first study treatment dose, whichever is
             longer, or participation in any other interventional clinical study.

         15. Prior use of radiation therapy within 4 weeks of enrollment.

         16. History of other malignancy within 5 years prior to screening, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer.

         17. History of illicit drug or alcohol abuse within 12 months prior to screening, in the
             investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Wróbel, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USK Wrocław</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomasz Wróbel, MD, PhD</last_name>
    <phone>+48 501 419 272</phone>
    <email>wrobeltw@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominik Dytfeld, MD, PhD</last_name>
    <phone>+48 602 464 708</phone>
    <email>dytfeld@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniwersytecki Szpital kliniczy im. Jana Mikulicza-Radeckiego we Wrocławiu; Klinika Hematologii, Nowotworów Krwi Transplantacji Szpiku</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Wróbel, MD, PhD</last_name>
      <phone>+48 501 419 272</phone>
      <email>wrobeltw@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Agnieszka Szeremet, MD</last_name>
      <phone>+48 71 784 22 77</phone>
      <email>agnieszka.szeremet@wp.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Tomasz Wróbel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnieszka Szeremet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elżbieta Kalicińska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Dytfeld, MD, PhD</last_name>
      <phone>+48 602464708</phone>
      <email>dytfeld@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Elżbieta Gwazdacz-Magiera</last_name>
      <phone>+48 535818919</phone>
      <email>egm1@tlen.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Dominik Dytfeld, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Nowicki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomasz Szczepanik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bartosz Małecki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Matuszak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

